Published on 20 Oct 2022 on Zacks via Yahoo Finance
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill Biopharma RDHL surged 46.6% on Oct 19 after the company reported that it has been granted a further method of use patent by the United States Patent and Trademark Office (USPTO) for its investigational pipeline COVID-19 candidate, opaganib.
The new patent for opaganib, which expires in 2041, aims to inhibit COVID-19 in a subgroup of patients with pneumonia, requiring supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%.
The patent protects data from a global post-hoc analysis from the phase II/III double-blind, placebo-controlled study evaluating opaganib in adult hospitalized COVID-19 patients with pneumonia.